Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AIDS Drugs Effective against Resistant Virus Needed
September 15, 2008
- Yamato Will Not Be Able to Be Profitable with Generics Alone: Mr Kumakura
September 15, 2008
- Publicity on Effective Migraine Treatment Needed: GSK Seminar
September 15, 2008
- Will Distribution Practices Be Improved? Part 1
September 15, 2008
- Next Generation of Antidiabetic Drugs Discussed: Tokyo Seminar
September 15, 2008
- Suzuken Expects Price Settlement Rate of Over 70% at the End of September
September 15, 2008
- No Subjective Symptoms in 27% of Glaucoma Patients with Impairment of Half of Visual Field
September 15, 2008
- World's 1st Drug for Idiopathic Pulmonary Fibrosis Recommended for Approval
September 15, 2008
- Shionogi to Enter US Market by Acquiring Sciele
September 15, 2008
- DSP to Design Independent US Marketing System by Mid-2009
September 15, 2008
- Kowa to Start Independent Marketing of Livalo in the US in 2010
September 15, 2008
- BD Enters Market for Cytodiagnostic Systems for Cervical Cancer
September 8, 2008
- Sanwa Kagaku Licenses SK-0403 to ChoongWae in South Korea
September 8, 2008
- Vascular Embolization Set for AVM Recommended for Approval
September 8, 2008
- Shionogi to Directly Enter US Market by Acquiring Sciele Pharma
September 8, 2008
- R&D NEWS IN BRIEF
September 8, 2008
- Astellas Aims at Top Market Share in Japan
September 8, 2008
- 4 Healthcare Clusters to Focus on 4 Fields
September 8, 2008
- Prevent Recurrence of Stroke: Prof. Hasegawa
September 8, 2008
- Recommending Hp Eradication in All Infected Persons: JSHR
September 8, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…